Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go

Executive Summary

FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor

You may also be interested in...



Public Citizen’s Health Group Changes Leadership, But Wolfe Remains On Prowl

Wolfe steps down to become senior advisor but remains a vocal critic of the pharmaceutical industry and FDA, as his appearance at the Avandia advisory committee meeting demonstrated.

FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”

One of the more interesting revelations from the House Energy and Commerce Committee's investigation into the ENHANCE trial is a document that may help explain why the Vytorin TV ads were pulled - and how FDA is handling questions about product efficacy in the current environment

FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”

One of the more interesting revelations from the House Energy and Commerce Committee's investigation into the ENHANCE trial is a document that may help explain why the Vytorin TV ads were pulled - and how FDA is handling questions about product efficacy in the current environment

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel